FORD OEM 14-16 Transit Connect 2.5L-L4-Battery Terminal or Box Cover CV6Z10A659B Car & Truck Batteries


  1. Home
  2. FORD OEM 14-16 Transit Connect 2.5L-L4-Battery Terminal or Box Cover CV6Z10A659B
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
FORD OEM 14-16 Transit Connect 2.5L-L4-Battery Terminal or Box Cover CV6Z10A659B
Condition: New Genuine OEM: Yes
Category 3: Battery Warranty: 2 Year
Superseded Part Number: CV6Z-10A659-A Quantity: 1
Other Part Number: CV6Z-10A659-A SKU: 111:CV6Z*10A659*B
Item Name: Battery Cover Brand:

Ford

Part Ref# on Diagram: ONLY PART REFERENCE #4 ON THE DIAGRAM IS INCLUDED Manufacturer Part Number:

CV6Z10A659B

Quantity Needed: 1 Category 2: Electrical
Category 1: Electrical Fitment Type: Direct Replacement
UPC:

Does not apply

published on tue nov 09 2021

FORD OEM 14-16 Transit Connect 2.5L-L4-Battery Terminal or Box Cover CV6Z10A659B Car & Truck Batteries

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

FORD OEM 14-16 Transit Connect 2.5L-L4-Battery Terminal or Box Cover CV6Z10A659B Car & Truck Batteries

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS